Home > Insider Trading > Chinook Therapeutics Inc. > Profile

Chinook Therapeutics Inc. (KDNY)

Sector: Pharmaceutical Preparations

Related Insiders

James Andrew King, Chief Scientific Officer, 2022-04-13
Versant Venture Capital Vii, L.p., Large Shareholder, 2022-04-06
Versant Voyageurs I Parallel, L.p., Large Shareholder, 2022-04-06

James Andrew King, Chief Scientific Officer, 2022-04-13
Versant Venture Capital Vii, L.p., Large Shareholder, 2022-04-06
Versant Voyageurs I Parallel, L.p., Large Shareholder, 2022-04-06
Versant Voyageurs I, L.p., Large Shareholder, 2022-04-06
Davis Jerel, Large Shareholder, Director, 2022-04-06
Mahesh Krishnan, Director, 2022-04-05
Eric Bjerkholt, Chief Financial Officer, 2022-02-15
Alan Glicklich, Chief Medical Officer, 2022-02-15
Eric Dobmeier, President, Ceo, 2022-02-15
Tom Frohlich, Chief Operating Officer, 2022-02-15
Srinivas Akkaraju, Director, 2021-11-17
Mariner William Greenman, Director, 2021-10-22
Dolca Thomas, Director, 2021-06-08
Ross Haghighat, Director, 2021-06-08
Renee Michelle Griffin, Director, 2021-06-08
T Stephen Isaacs, President And Ceo, 2020-09-18
Blaine Templeman, Chief Legal Officer, 2020-09-18
Celeste Ferber, Svp, Gc And Secretary, 2020-09-18
Sa Dimitry Nuyten, Chief Medical Officer, 2020-08-11
G William Kachioff, Interim Cfo, 2020-06-03
Henry David Mack, Director, 2020-05-29
Frank Karbe, Director, 2020-05-29
A Stephen Sherwin, Director, 2020-05-28
Monaghan Stephanie Obrien, Director, 2020-05-28
Andrea Elsas Van, Chief Scientific Officer, 2020-02-26
H James Welch, See Remarks, 2019-07-15
Jennifer Lew, Chief Financial Officer, 2019-05-03
Jr Floyd Daniel Hoth, Interim Chief Medical Officer, 2018-12-07
Natalie Sacks, Chief Medical Officer, 2018-09-14
Frank Mccormick, Director, 2018-06-08
Gerald Chan, Director, 2018-06-08
Ltd Investments (Vi) Venture Morningside, Large Shareholder, 2018-02-13
W Gregory Schafer, Chief Operating Officer, 2018-01-27
G. Dirk Brockstedt, Evp Of Research And Dev., 2018-01-04
W. Thomas Dubensky, Chief Scientific Officer, 2017-08-12
A. Lois And E. John Rogers, Large Shareholder, 2015-04-22
Ltd Keen Ultimate, Large Shareholder, 2015-04-22

Show All Insiders (37)

Hedge Fund Popularity

Display

Display Share Price

Display Large Version

Hedge Fund Holdings

Filing Period:

Last updated on August 16, 2021, 3:02 pm based on SEC 13F filings Last update: August 16, 2021, 3:02 pm

No.	Hedge Fund	Value (x$1000)	% Port
1.	Rubric Capital Management David Rosen	$0	0%
2.	D E Shaw D. E. Shaw	$0	0%
3.	Burrage Capital Management Christiana Goh Bardon	$0	0%
4.	Suvretta Capital Management Aaron Cowen	$0	0%
5.	Point72 Asset Management Steve Cohen	$0	0%

Insider Trading: Purchases See All

Insider	Price	Amount	Relationship	Remaining Holdings	Date	Form 4
Akkaraju	$14.00	1,215,000	Director	4,591,888	2021-11-15	Filing
Dobmeier	$12.00	2,000	Officer, Director	109,837	2021-09-20	Filing
Akkaraju	$11.98	208,500	Director	3,376,888	2021-08-18	Filing
Dobmeier	$12.00	3,000	Officer, Director	107,837	2021-08-19	Filing
Dobmeier	$11.74	7,000	Officer, Director	104,837	2021-08-18	Filing

Insider Trading: Sales See All

Insider	Price	Amount	Relationship	Remaining Holdings	Date	Form 4
King	$15.36	5,000	Officer	5,897	2022-04-11	Filing
King	$13.00	2,500	Officer	5,897	2022-02-18	Filing
Bjerkholt	$12.74	895	Officer	22,203	2022-02-11	Filing
King	$12.74	2,498	Officer	8,397	2022-02-11	Filing
Glicklich	$12.74	2,391	Officer	7,891	2022-02-11	Filing

Institutional Investors' Holdings

Filing Period:

No.	Name	Value (x$1000)	% Port
1.	Prudential Financial Inc	$0	0%
2.	Acadian Asset Management Llc	$0	0%
3.	Rhumbline Advisers	$0	0%
4.	Cambridge Investment Research Advisors, Inc.	$0	0%
5.	Manufacturers Life Insurance Company, The	$0	0%

News See All

Click here to See All News

Chinook Therapeutics Inc. (KDNY)

Related Insiders

Hedge Fund Popularity

3 Stocks to Buy According to Devesh Gandhi’s SilverArc Capital

Hedge Funds Are Crazy About Chinook Therapeutics, Inc. (KDNY)

5 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs’ Samsara BioCapital